AML cells in patients refractory to HSCT downregulate the HLA II genes [10, 11], and deregulate co-stimulatory molecules [11], both of which are critical to activate CD4+ T cells that help CD8+ T cells. Here, CD8A is linked to acute myeloid leukemia.